- Home
- LPCN vs SPWRW Comparison
LPCN vs SPWRW Comparison
Compare LPCN & SPWRW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPCN
- SPWRW
- Stock Information
- Founded
- LPCN 1997
- SPWRW N/A
- Country
- LPCN United States
- SPWRW United States
- Employees
- LPCN N/A
- SPWRW N/A
- Industry
- LPCN Biotechnology: Pharmaceutical Preparations
- SPWRW Semiconductors
- Sector
- LPCN Health Care
- SPWRW Technology
- Exchange
- LPCN Nasdaq
- SPWRW Nasdaq
- Market Cap
- LPCN 16.1M
- SPWRW 15.5M
- IPO Year
- LPCN N/A
- SPWRW N/A
- Fundamental
- Price
- LPCN $3.16
- SPWRW $0.14
- Analyst Decision
- LPCN Strong Buy
- SPWRW
- Analyst Count
- LPCN 1
- SPWRW 0
- Target Price
- LPCN $10.00
- SPWRW N/A
- AVG Volume (30 Days)
- LPCN 22.1K
- SPWRW N/A
- Earning Date
- LPCN 05-08-2025
- SPWRW N/A
- Dividend Yield
- LPCN N/A
- SPWRW N/A
- EPS Growth
- LPCN N/A
- SPWRW N/A
- EPS
- LPCN N/A
- SPWRW N/A
- Revenue
- LPCN $3,674,834.00
- SPWRW N/A
- Revenue This Year
- LPCN N/A
- SPWRW N/A
- Revenue Next Year
- LPCN N/A
- SPWRW N/A
- P/E Ratio
- LPCN N/A
- SPWRW N/A
- Revenue Growth
- LPCN N/A
- SPWRW N/A
- 52 Week Low
- LPCN $2.75
- SPWRW N/A
- 52 Week High
- LPCN $11.79
- SPWRW N/A
- Technical
- Relative Strength Index (RSI)
- LPCN 48.60
- SPWRW N/A
- Support Level
- LPCN $2.68
- SPWRW N/A
- Resistance Level
- LPCN $3.46
- SPWRW N/A
- Average True Range (ATR)
- LPCN 0.33
- SPWRW 0.00
- MACD
- LPCN -0.02
- SPWRW 0.00
- Stochastic Oscillator
- LPCN 51.97
- SPWRW 0.00
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.